Interferon alpha-2a - Ainos/Hayashibara
Alternative Names: IFN-alpha lozenges; MOR 22; Natural human lymphoblastoid interferon-alpha; VeldonaLatest Information Update: 05 Nov 2023
At a glance
- Originator Hayashibara
- Developer Ainos; CytoPharm; Hayashibara; Mochida Pharmaceutical; NOBEL ILAC; Otsuka Pharmaceutical
- Class Antineoplastics; Antivirals; Interferons
- Mechanism of Action Immunomodulators; Interferon alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Behcet's syndrome; Common cold; Influenza virus infections; Sjogren's syndrome
Highest Development Phases
- Marketed Hepatitis B; Hepatitis C; Myeloid leukaemia; Renal cell carcinoma
- Phase III Sjogren's syndrome
- Phase II Influenza virus infections
- Preclinical COVID 2019 infections
- No development reported Behcet's syndrome; Human papillomavirus infections; Solid tumours; Thrombocytopenia
- Discontinued Chronic obstructive pulmonary disease; Fibromyalgia; HIV infections; Liver cancer; Polycythaemia vera; Pulmonary fibrosis; Skin disorders; Thrombocytosis
Most Recent Events
- 19 Sep 2023 Ainos plans a phase III trial in Human papillomavirus infections
- 18 Sep 2023 Ainos plans to hold a pre-IND meeting with the US FDA in advance of planned phase III clinical studies of Interferon alpha-2a for Human papillomavirus infections
- 18 Sep 2023 Interferon alpha-2a - Ainos/Hayashibara receives Orphan Drug status for Human papillomavirus infections in USA